About

Nandrolone Wikipedia

Contents

Nandrolone

Medical uses

Non-medical uses

Side effects

Pharmacology

Pharmacodynamics

Anabolic and androgenic activity

Pharmacokinetics

Chemistry

Derivatives

Esters

Anabolic steroids

Progestins

Synthesis

Detection in body fluids

History

Society and culture

Generic names

Doping in sports

Research

References

Further reading




Nandrolone

------------



General description



Nandrolone (5α-androst-1-en-17β-ol-3-one) is a naturally occurring anabolic–androgenic steroid (AAS) that belongs to the class of 19-nortestosterone derivatives. It has been used clinically as an injectable therapy for various conditions, including anemia and osteoporosis, due to its ability to stimulate erythropoiesis and bone density. In addition, it has been abused by athletes and bodybuilders because of its muscle‑building effects.



Structure





IUPAC name: 5α-androst-1-en-17β-ol-3-one


Formula: C19H28O2



Key pharmacological properties



Anabolic activity (muscle growth)


Mild androgenic activity


Oral bioavailability is low; typically administered by intramuscular injection.



Clinical indications



Treatment of anemia, particularly in patients with chronic kidney disease.


Prevention and treatment of osteoporosis in post‑menopausal women.


Adjunct therapy for bone marrow suppression following chemotherapy or radiation.



Side effects



Common: nausea, vomiting, headache, dizziness.


Serious: thromboembolic events (deep vein thrombosis, pulmonary embolism), hypertension, hepatic dysfunction.



Contraindications



History of venous thromboembolism


Uncontrolled hypertension


Hepatic disease



Drug interactions



CYP3A4 inhibitors may increase serum levels; caution with drugs such as ketoconazole.


Anticoagulants (warfarin) can have additive effects; monitor INR.



Patient counseling points



Take the medication exactly as prescribed: Do not skip doses or take extra amounts.


Watch for side effects: If you experience chest pain, swelling of your legs, shortness of breath, or a sudden headache, contact your healthcare provider immediately.


Avoid alcohol and certain medications that can increase bleeding risk (e.g., aspirin).


Maintain regular follow‑up appointments to monitor your blood pressure and any potential side effects.







3. References




Clinical Practice Guidelines for the Management of Hypertension – American College of Cardiology/American Heart Association, 2022.


Jaffe JL, et al. "New therapeutic agents in hypertension." JACC. 2023;78(5):e45‑e60.


Smith R., et al. "Efficacy and safety of the novel dual-acting agent (Compound X) in resistant hypertension: a randomized controlled trial." Hypertension 2024;74(1):12‑24.


National Center for Biotechnology Information, PubMed Central – Search results for "dual agonist hypertension treatment" 2023–2024.



(Note: The above references are illustrative and do not correspond to actual publications.)

---



Prepared by:

Your Name, MD, PhD (Nephrology & Hypertension)

Research Associate, Department of Medicine

Institution




---
End of Memorandum.

Female